On August 16, 2022, RainMed Medical Co., LTD. (hereinafter referred to as "RainMed", stock code: 2297.HK) and Angiotec （Tianjin）Technology Co., Ltd. (hereinafter referred to as "Angiotec”) held a signing ceremony for strategic cooperation in Tianjin. Mr. Yunfei Huo, Chairman of the Board, Executive Director and Chief Executive Officer of RainMed and Mr. Da Zhuo, General Manager of Angiotec signed the agreement on behalf of both companies. Mr. Yonghui Lv, Executive Director and co-Chief Executive Officer of RainMed also attended the meeting.

This time, the strategic cooperation between domestic high-tech enterprise of precise vascular diagnosis and treatment and domestic outstanding enterprises of innovative medical devices will give full play to the advantages of advanced technology research and development of both sides, accelerate the creation of an integrated solution for cardiovascular operating room, and contribute Chinese wisdom to promoting the development of global precise coronary diagnosis and treatment.

As a high-tech enterprise in the field of precision diagnosis and treatment in China, RainMed Medical has excellent advantages in product research and development. It has launched a series of epoch-making diagnosis and treatment products for vascular diseases. In terms of marketing, the company has built a perfect marketing system at home and abroad, achieved a breakthrough in the export of domestic FFR equipment. It has been widely recognized by the clinical and capital markets and finally listed on the main board of the Hong Kong Stock Exchange successfully. Angiotec, as a key supporting enterprise of Tianjin Municipal Government and Tianjin Medical Products Administration, has the production capacity of the whole process and a perfect patent system. It has also built a strict technical barrier in the industry and continuously launched a series of high-tech medical products to solve the pain points of the traditional interventional surgery industry. In terms of the strategic cooperation, the two sides would combine their respective advantages on research and development, production, marketing, etc., promote all-round, multi-field and in-depth cooperation, jointly launch more innovation achievements, make high-quality diagnosis and treatment plan, expand RainMed’s international business landscape, and promote the development of global precise coronary diagnosis and treatment.

Mr. Yunfei Huo, Chairman of the Board, Executive Director and Chief Executive Officer of RainMed said: RainMed Medical is committed to differentiated research and development in the field of vascular interventional surgery robot, launching vascular interventional surgery robots covering the whole process of diagnosis and treatment, freeing clinicians from tedious and time-consuming work, serving clinicians, and promoting the development of vascular health in China. As an outstanding enterprise of high-tech medical devices in China, Angiotech has launched a series of high-quality medical devices through continuous innovation and research in order to improve the operation mode and optimize the operation process. The strategic cooperation of RainMed Medical and Angiotech will be regarded as a strong cooperation and complementarity. It will greatly accelerate the implementation of the strategic goal of unmanned operating room, and jointly open a new chapter of coronary intervention diagnosis and treatment.

Mr. Da Zhuo, general manager of Angiotech, said that Angiotech has independent medical device research and development and sales capacity. In the research and development, the company has actively carried out cooperation with domestic top hospitals and R&D institutions. In marketing, the company has invested a lot of resources, its products and services have covered more than 20 provinces and cities nationwide. RainMed Medical has a professional team, a reliable expert team, strong scientific research strength, rich patent layout, perfect production system, and a strong sales team. This time, Angiotech will carry out in-depth and multi-level strategic cooperation with RainMed Medical, jointly create innovative scientific research products, promote product sales and hospital admission, enhance the company's brand value, and jointly enter a new stage of development.

Mr. Yonghui Lv, Executive Director and co-Chief Executive Officer of RainMed, said that RainMed Medical has excellent ability of scientific research transformation and commercial landing. The series of products developed by the company have been widely recognized by experts and scholars in the industry. At the same time, RainMed Medical has successfully established two marketing centers at home and abroad, and formed marketing teams of more than 100 people. Up to now, RainMed Medical's commercial network has covered 29 provinces and autonomous regions in China. It has also built a distribution network in Europe, Africa, and Southeast Asia. Angiotech is an enterprise which covers a full-range of vascular intervention consumables. Its innovative products largely solve the pain points in the field of traditional intervention. In this strategic cooperation, both companies will expand the penetration rate of high-quality products at home and abroad according to their respective resource advantages, and jointly promote the development of the global medical industry.

After the signing ceremony, Da Zhuo, general manager of Angiotech, led the executive team of RainMed Medical to visit Kangtai Zhida Science and Technology Industrial Park approved by Tianjin government and jointly invested by Angiotech.

RainMed Medical’s Vice President and Chairman Secretary Kangjian Liu, Chief Technology Officer Guangzhi Liu, Director of Sales Ning Duan, Director of International Marketing Department Kefu Xia, and Angiotech Vice General Manager Shuxin Li, Vice General Manager Jincai Sun, Sales Director Kai Li, financial manager Jianlong Jia, Quality Department Manager Xiaoyang Wang and other guests also attended the signing ceremony of the strategic cooperation.